by The U.S. hemophilia treatment market is witnessing growth owing to rising prevalence of bleeding disorders such as hemophilia A and hemophilia B. Hemophilia refers to a rare genetic disorder where blood is unable to clot properly resulting in uncontrolled bleeding. Factors causing hemophilia include deficiency of coagulation factors such as factor VIII and factor IX. Various treatment options available in the market include replacement therapy, desmopressin medication, and antifibrinolytic agents. Recombinant factor VIII and factor IX are frequently used for replacement therapy as they effectively help avoid and control bleeding episodes. The high treatment costs associated with hemophilia have been driving investments from pharmaceutical and biotech companies in development of novel drug formulations and gene therapy.
The Global U.S. Hemophilia Treatment Market Size is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the U.S. hemophilia treatment are Takeda Pharmaceutical Company Limited, Sanofi, Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc. and Among Others. Key players are engaged in new product launches, partnerships and acquisitions to strengthen their market position. For instance, in 2022 Takeda Pharmaceutical Company launched its Hemlibra drug targeting people living with hemophilia A with factor VIII inhibitors.
The growing demand for hemophilia treatment drugs in the U.S. can be attributed to the increasing prevalence of bleeding disorders in the country. As per recent statistics, hemophilia A affects around 1 in 5,000 male births in the U.S. Favorable reimbursement policies and improvements in healthcare infrastructure have also been supporting patients’ access to advanced treatment options.
Furthermore, pharmaceutical companies are expanding their operations globally with a focus on the U.S. market. For example, in 2021 Swedish Orphan Biovitrum opened a new production plant in Pennsylvania to ramp up supply of hemophilia drugs to the U.S. Meanwhile, partnerships with key hospitals are helping providers strengthen their research capabilities and clinical trial operations.
Market Key Trends
The rise in gene therapy clinical trials offers a major trend in the U.S. hemophilia treatment market. Promising results from Phase III studies evaluating the potential of gene therapy to provide long-term cure are attracting further R&D investments. In 2022, BioMarin Pharmaceutical announced plans to file a regulatory application for its valoctocogene roxaparvovec gene therapy after the drug met primary endpoints in late-stage trials. Such novel treatment options may help reduce reliance on frequent infusions in future.
Porter’s Analysis
Threat Of New Entrants: High capital requirements for manufacturing facilities and R&D activities poses as a barrier.
Bargaining Power Of Buyers: Large pharmaceutical companies have stronger bargaining power against buyers owing to their product portfolios.
Bargaining Power Of Suppliers: Suppliers of raw materials and contract manufacturers have moderate bargaining power due to few alternatives.
Threat Of New Substitutes: Low threat as hemophilia treatments have no close substitutes for clotting factor deficiencies.
Competitive Rivalry: Intense competition exists between large pharmaceutical companies due to differentiation in product offerings and patents.
Geographical Regions
The United States accounts for the largest market share currently estimated to generate a value of around $4.21 billion by 2024 owing to well developed healthcare infrastructure and high adoption rates of factor replacement therapies.
The Asia Pacific region excl. Japan is poised to grow at the fastest CAGR during the forecast period due to rising healthcare spending, increasing diagnosis rates and growing patient awareness in developing economies like India and China.
What Are The Key Data Covered In This U.S. Hemophilia Treatment Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the U.S. Hemophilia Treatment Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the U.S. Hemophilia Treatment Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- U.S. Hemophilia Treatment Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of U.S. Hemophilia Treatment Market vendors
FAQ’S
Q.1 What are the main factors influencing the U.S. Hemophilia Treatment market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top U.S. Hemophilia Treatment Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the U.S. Hemophilia Treatment market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
